RP-3500 is an oral ATR kinase inhibitor and Ph. II clinical candidate for advanced solid tumors with ATRi-sensitizing mutations, alone or in combination with talazoparib (PARPi) or gemcitabine. Reviewer Anthony Vaganos says, “An ATR molecule ( ceralasertib ) is in clinical trials but studies in two different tumors in combination with PARP [...]
< 1 minute read
Jan. 17, 2022
RP-3500 is an Oral ATR Kinase Inhibitor
RP-3500
ATR kinase inhibitor phase I/IIa candidate for advanced solid tumors from lipid-kinase inhibitor scaffold Molecular Cancer Therapeutics Repare Therapeutics, Saint-Laurent, CAN